{
  "items": "50",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "(HIMS) Risk Channels and Responsive Allocation",
      "url": "https://news.stocktradersdaily.com/news_release/1/HIMS_Risk_Channels_and_Responsive_Allocation_122025114401_1766292241.html",
      "time_published": "20251221T000855",
      "authors": [
        "Thomas H. Kee Jr"
      ],
      "summary": "This article provides a stock analysis for Hims & Hers Health Inc. Class A (NASDAQ: HIMS), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It details three AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014along with multi-timeframe signal analysis for support and resistance levels. The analysis reports elevated downside risk due to a lack of additional long-term support signals.",
      "banner_image": "https://news.stocktradersdaily.com/media/690608_HIMS_graph.jpg",
      "source": "Stock Traders Daily",
      "category_within_source": "General",
      "source_domain": "Stock Traders Daily",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.915010"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.720128"
        }
      ],
      "overall_sentiment_score": -0.232148,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.237860",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "(HIMS) Movement as an Input in Quant Signal Sets",
      "url": "https://news.stocktradersdaily.com/news_release/91/HIMS_Movement_as_an_Input_in_Quant_Signal_Sets_120925095802_1765335482.html",
      "time_published": "20251209T215800",
      "authors": [
        "Luke Campbell"
      ],
      "summary": "This article from Stock Traders Daily discusses Hims & Hers Health Inc. (NASDAQ: HIMS), highlighting strong sentiment across all time horizons supporting an overweight bias. It presents specific AI-generated trading strategies for HIMS, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The analysis also points to an exceptional 112.6:1 risk-reward setup.",
      "banner_image": "https://news.stocktradersdaily.com/media/682654_HIMS_graph.jpg",
      "source": "Stock Traders Daily",
      "category_within_source": "General",
      "source_domain": "Stock Traders Daily",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.949334"
        }
      ],
      "overall_sentiment_score": 0.416103,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.418023",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "HIMS CLASS ACTION FILED: Kessler Topaz Meltzer & Check, LLP Reminds Investors - a Securities Fraud Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. (HIMS)",
      "url": "https://natlawreview.com/press-releases/hims-class-action-filed-kessler-topaz-meltzer-check-llp-reminds-investors",
      "time_published": "20251206T040218",
      "authors": [
        "NULL"
      ],
      "summary": "Kessler Topaz Meltzer & Check, LLP announced that a securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS). The lawsuit alleges that Hims & Hers made materially false or misleading statements and failed to disclose that it was deceptively promoting illegitimate versions of Wegovy, which put patient safety at risk and jeopardized its collaboration with Novo Nordisk. Investors who purchased Hims & Hers securities between April 29, 2025, and June 23, 2025, are encouraged to contact the firm by August 25, 2025, to discuss potentially being appointed as a lead plaintiff.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1050349",
      "source": "The National Law Review",
      "category_within_source": "General",
      "source_domain": "The National Law Review",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.911235"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.835978"
        }
      ],
      "overall_sentiment_score": -0.619679,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.616946",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Boughton, Hims & Hers health CLO, sells $112k in shares",
      "url": "https://www.investing.com/news/insider-trading-news/boughton-hims--hers-health-clo-sells-112k-in-shares-93CH-4353738",
      "time_published": "20251118T050914",
      "authors": [
        "Investing.com"
      ],
      "summary": "Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc. (NASDAQ:HIMS), sold 2,637 shares valued at $112,151 on November 10, 2025. This transaction was executed under a Rule 10b5-1 trading plan. The sale followed a quarter where Hims & Hers exceeded analyst expectations in revenue, EBITDA, and EPS, despite narrowing its 2025 revenue guidance.",
      "banner_image": "https://i-invdn-com.investing.com/news/international_newspapers_69x52._800x533_L_1419494241.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.939843"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.821460"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.743494"
        }
      ],
      "overall_sentiment_score": 0.257097,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.994531",
          "ticker_sentiment_score": "-0.204702",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.636252",
          "ticker_sentiment_score": "0.324437",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.619987",
          "ticker_sentiment_score": "0.329038",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ORCL",
          "relevance_score": "0.580032",
          "ticker_sentiment_score": "0.321271",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AVGO",
          "relevance_score": "0.584650",
          "ticker_sentiment_score": "0.308933",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2% (HIMS:NYSE)",
      "url": "https://seekingalpha.com/news/4522892-hims-hers-health-effects-new-up-to-250m-stock-buyback-program-shares-up-2",
      "time_published": "20251117T082000",
      "authors": [
        "Mary Christine Joy"
      ],
      "summary": "Hims & Hers Health (HIMS) has announced a new share repurchase program of up to $250 million for its outstanding Class A common stock, to be executed over the next three years. This news follows the completion of its previous $100 million buyback program and led to a pre-market stock increase of 2.76% to $38.00.",
      "banner_image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2202221502/image_2202221502.jpg?io=getty-c-w630",
      "source": "Seeking Alpha",
      "category_within_source": "General",
      "source_domain": "Seeking Alpha",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.924910"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.811385"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.712723"
        }
      ],
      "overall_sentiment_score": 0.427297,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.447563",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Hims & Hers Health board approves $250 million share repurchase program",
      "url": "https://www.investing.com/news/sec-filings/hims--hers-health-board-approves-250-million-share-repurchase-program-93CH-4362296",
      "time_published": "20251117T081600",
      "authors": [
        "Investing.com"
      ],
      "summary": "Hims & Hers Health (NYSE:HIMS) announced its board has approved a new $250 million share repurchase program for its Class A common stock, set to expire in November 2028. This follows the complete utilization of a previous $100 million repurchase program. The company will repurchase shares through various methods, and the program can be suspended or discontinued at any time.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_10_800x533_L_1420026292.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.942368"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.804463"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.719265"
        }
      ],
      "overall_sentiment_score": 0.447337,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.449982",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Hims & Hers Health stock rises after announcing $250 million buyback program",
      "url": "https://www.msn.com/en-us/money/other/hims-hers-health-stock-rises-after-announcing-250-million-buyback-program/ar-AA1QBIDr",
      "time_published": "20251117T060909",
      "authors": [],
      "summary": "Hims & Hers Health (HIMS) stock rose in premarket trading after the company announced a $250 million share repurchase program. The buyback program is authorized for two years and will commence immediately. The company expects the program to be immediately accretive to shareholder value.",
      "banner_image": null,
      "source": "MSN",
      "category_within_source": "General",
      "source_domain": "MSN",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.925550"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.821744"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.718333"
        }
      ],
      "overall_sentiment_score": 0.303097,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.444677",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.609788",
          "ticker_sentiment_score": "0.221550",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization",
      "url": "https://investors.hims.com/news/news-details/2025/Hims--Hers-Health-Inc--Announces-250-Million-Share-Repurchase-Program-Authorization/default.aspx",
      "time_published": "20251117T040218",
      "authors": [
        "NULL"
      ],
      "summary": "Hims & Hers Health, Inc. has announced a new share repurchase program, authorizing up to $250 million of its Class A common stock over the next three years. This program follows the successful completion of a previous $100 million repurchase initiative. The company aims to capitalize on perceived valuation disconnects and deliver value to shareholders, leveraging its strong balance sheet and projected cash flows.",
      "banner_image": "NULL",
      "source": "Hims Investor Relations",
      "category_within_source": "General",
      "source_domain": "Hims Investor Relations",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.936800"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.801065"
        },
        {
          "topic": "finance",
          "relevance_score": "0.713986"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.614562"
        }
      ],
      "overall_sentiment_score": 0.493997,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.484991",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Hims & Hers health authorizes $250 million share repurchase program",
      "url": "https://www.msn.com/en-us/money/markets/hims-hers-health-authorizes-250-million-share-repurchase-program/ar-AA1QBl1Q?ocid=finance-verthp-feeds",
      "time_published": "20251117T040218",
      "authors": [],
      "summary": "Hims & Hers Health, Inc. has announced that its Board of Directors authorized a $250 million share repurchase program. This program is in effect for one year, allowing the company to repurchase shares of its common stock through various methods.",
      "banner_image": null,
      "source": "MSN",
      "category_within_source": "General",
      "source_domain": "MSN",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.936850"
        },
        {
          "topic": "finance",
          "relevance_score": "0.708909"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.641460"
        }
      ],
      "overall_sentiment_score": 0.434488,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.424533",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Hims & Hers Health Announces New Share Repurchase Program",
      "url": "https://www.tradingview.com/news/tradingview:7cc33cdbe8aa9:0-hims-hers-health-announces-new-share-repurchase-program/",
      "time_published": "20251116T070933",
      "authors": [
        "NULL"
      ],
      "summary": "Hims & Hers Health, Inc. has announced a new share repurchase program authorizing the company to buy back up to $250 million in Class A stock. This program will expire on November 11, 2028, and repurchases will be discretionary based on market conditions. This follows the full utilization of a previous $100 million repurchase program by November 2025.",
      "banner_image": "NULL",
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.913272"
        },
        {
          "topic": "finance",
          "relevance_score": "0.835327"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.646556"
        }
      ],
      "overall_sentiment_score": 0.473932,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.455385",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Rosen Law Firm Encourages Hims & Hers Health, Inc. Investors to Inquire About Securities Class Action Investigation \u2013 HIMS",
      "url": "https://www.businesswire.com/news/home/20250623770960/en/Rosen-Law-Firm-Encourages-Hims-Hers-Health-Inc.-Investors-to-Inquire-About-Securities-Class-Action-Investigation-HIMS",
      "time_published": "20251102T000000",
      "authors": [],
      "summary": "The Rosen Law Firm has launched an investigation into potential securities claims against Hims & Hers Health, Inc. following allegations of misleading business information. This probe comes after Novo Nordisk terminated its collaboration with Hims & Hers, citing concerns about illegal mass compounding and deceptive marketing, which led to an over 28% drop in Hims & Hers' stock. Investors are encouraged to contact the firm to join a prospective class action seeking compensation for their losses.",
      "banner_image": null,
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.849346"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.748789"
        }
      ],
      "overall_sentiment_score": -0.731899,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.721708",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc.",
      "url": "https://www.globenewswire.com/news-release/2025/10/29/3176665/0/en/LEVI-KORSINSKY-ISSUES-CORRECTION-Securities-Fraud-Class-Action-Against-Hims-Hers-Health-Inc.html",
      "time_published": "20251029T112200",
      "authors": [
        "Levi & Korsinsky",
        "LLP"
      ],
      "summary": "Levi & Korsinsky, LLP has issued a correction regarding a securities fraud class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS). Previously, it was incorrectly stated that Levi & Korsinsky filed the case, but it was actually filed by Glancy Prongay & Murray LLP. The lawsuit alleges that Hims & Hers Health made false statements and concealed deceptive practices related to the promotion of \"knockoff\" versions of Wegovy\u00ae, putting patient safety at risk and jeopardizing its collaboration with Novo Nordisk.",
      "banner_image": "https://ml.globenewswire.com/media/YjZlY2Y0NmUtYzU1Ni00Y2FhLTlmOGQtNTNhYjkzMjM0YmZiLTEwMzIyOTMtMjAyNS0xMC0yOS1lbg==/tiny/Levi-Korsinsky-LLP.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.715404"
        }
      ],
      "overall_sentiment_score": -0.410912,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.418019",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Avoiding Lag: Real-Time Signals in (HIMS) Movement - news.stocktradersdaily.com",
      "url": "https://news.stocktradersdaily.com/news_release/114/Avoiding_Lag:_Real-Time_Signals_in_HIMS_Movement_101825042202_1760818922.html",
      "time_published": "20251018T162202",
      "authors": [
        "Manual News Generation - Contributor; Thomas H. Kee Jr."
      ],
      "summary": "This article provides an analysis of Hims & Hers Health Inc. (HIMS) movement with real-time signals and trading strategies. It highlights a strong near-term sentiment and a significant risk-reward setup targeting a 25.6% gain against a 0.3% risk. The report details specific institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.",
      "banner_image": "https://news.stocktradersdaily.com/media/650835_HIMS_graph.jpg",
      "source": "news.stocktradersdaily.com",
      "category_within_source": "General",
      "source_domain": "news.stocktradersdaily.com",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.715183"
        },
        {
          "topic": "technology",
          "relevance_score": "0.343977"
        }
      ],
      "overall_sentiment_score": 0.007344,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.340991",
          "ticker_sentiment_score": "0.037111",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Hims & Hers stock is failing to retain menopause gains and what comes next? - Invezz",
      "url": "https://invezz.com/news/2025/10/17/why-hims-hers-stock-is-failing-to-retain-menopause-gains-and-what-comes-next/",
      "time_published": "20251017T172615",
      "authors": [
        "Wajeeh Khan",
        "Devesh Kumar"
      ],
      "summary": "Hims & Hers Health Inc (NYSE: HIMS) stock is struggling to retain gains from its expansion into menopause-related treatments, with shares down nearly 30% from their year-to-date high. This decline follows the public disclosure of CEO Andrew Dudum selling over $11 million worth of shares, raising investor concerns about the company's long-term prospects. The article highlights that Hims & Hers faces challenges including a high forward P/E multiple, thin margins, persistent net losses, and growing competition, making its lofty valuation difficult to sustain.",
      "banner_image": "https://invezz.com/wp-content/uploads/2025/10/20251017_165829_yeohp.png",
      "source": "Invezz",
      "category_within_source": "General",
      "source_domain": "Invezz",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.926366"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.802408"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.719151"
        },
        {
          "topic": "technology",
          "relevance_score": "0.406245"
        },
        {
          "topic": "economy_macro",
          "relevance_score": "0.320261"
        }
      ],
      "overall_sentiment_score": 0.017688,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.329607",
          "ticker_sentiment_score": "0.030605",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hims & Hers Health (HIMS) Stock Tanks 13% after CEO Discloses Stock Sale - TipRanks",
      "url": "https://www.tipranks.com/news/hims-hers-health-hims-stock-tanks-13-after-ceo-discloses-stock-sale",
      "time_published": "20251017T164333",
      "authors": [
        "Vince Condarcuri"
      ],
      "summary": "Shares of Hims & Hers Health (HIMS) dropped 13% after CEO Andrew Dudum disclosed a significant stock sale totaling over $40 million in recent months. While the sales appear to be part of a pre-set investment plan involving stock options and vested restricted stock, the volume of sales has raised investor concern. Analysts currently have a Hold consensus rating on HIMS stock with an average price target implying a 4.2% downside risk.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2025/10/shutterstock_1825526441-1-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.800306"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.726583"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.608975"
        },
        {
          "topic": "finance",
          "relevance_score": "0.522977"
        }
      ],
      "overall_sentiment_score": 0.045821,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.316558",
          "ticker_sentiment_score": "0.001677",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Weight-Loss Drug Mania Shook Markets\u2014Now Hims & Hers Bets on a Menopause Care Boom - ts2.tech",
      "url": "https://ts2.tech/en/weight-loss-drug-mania-shook-markets-now-hims-hers-bets-on-a-menopause-care-boom/",
      "time_published": "20251017T155504",
      "authors": [
        "Mateusz Kaczmarek"
      ],
      "summary": "Hims & Hers Health launched a menopause and perimenopause care program, causing a significant stock surge and aiming for $1 billion in revenue for its Hers platform by 2026. The move positions menopause care as the potential \"next Ozempic\" in healthcare, tapping into a massive and underserved market. Despite stock volatility and analyst caution due to high valuation, the company hopes to leverage its telehealth model and recent expansions to justify its growth trajectory.",
      "banner_image": "https://ts2.tech/wp-content/uploads/2025/10/hims-stock.jpg.webp",
      "source": "ts2.tech",
      "category_within_source": "General",
      "source_domain": "ts2.tech",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.904432"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.843491"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.708949"
        },
        {
          "topic": "technology",
          "relevance_score": "0.621371"
        },
        {
          "topic": "economy_macro",
          "relevance_score": "0.429947"
        }
      ],
      "overall_sentiment_score": 0.021246,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.323856",
          "ticker_sentiment_score": "0.029762",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hims & Hers Health stock falls after Trump promises lower weight loss drug prices - Investing.com Canada",
      "url": "https://ca.investing.com/news/stock-market-news/hims--hers-health-stock-falls-after-trump-promises-lower-weight-loss-drug-prices-93CH-4253218",
      "time_published": "20251017T143710",
      "authors": [],
      "summary": "This article reports a client-side application error, indicating that the intended content about Hims & Hers Health stock falling due to Trump's promise on lower weight loss drug prices could not be loaded. Therefore, the actual content of the news story is unavailable.",
      "banner_image": null,
      "source": "Investing.com Canada",
      "category_within_source": "General",
      "source_domain": "Investing.com Canada",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.941691"
        },
        {
          "topic": "economy_fiscal",
          "relevance_score": "0.541298"
        }
      ],
      "overall_sentiment_score": 0.01157,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.339555",
          "ticker_sentiment_score": "0.048926",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hims & Hers Health Stock (HIMS) Opinions on Menopause Care Platform Launch - Quiver Quantitative",
      "url": "https://www.quiverquant.com/news/Hims+%26+Hers+Health+Stock+%28HIMS%29+Opinions+on+Menopause+Care+Platform+Launch",
      "time_published": "20251017T140200",
      "authors": [
        "Quiver DiscussionTracker"
      ],
      "summary": "Hims & Hers Health (HIMS) has launched a new menopause and perimenopause care platform, stirring mixed reactions on X regarding its stock performance and future potential. While some express optimism for the company's innovation in women's health, others voice concerns about regulatory scrutiny and market volatility. The article also details recent congressional and insider trading activities, as well as hedge fund movements and analyst ratings for HIMS.",
      "banner_image": "https://www.quiverquant.com/images/hims_rect_new.png",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.933891"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.737752"
        },
        {
          "topic": "finance",
          "relevance_score": "0.649728"
        },
        {
          "topic": "technology",
          "relevance_score": "0.414428"
        }
      ],
      "overall_sentiment_score": 0.040494,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.305560",
          "ticker_sentiment_score": "0.033778",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hims & Hers: Navigating Financial Challenges",
      "url": "https://www.timothysykes.com/news/hims-hers-health-inc.hims-news-2025_10_17/",
      "time_published": "20251017T131900",
      "authors": [
        "Timothy Sykes",
        "Bryce Tuohey",
        "Matt Monaco"
      ],
      "summary": "Hims & Hers Health Inc. (NYSE: HIMS) stock reportedly trended down by -2.4% following strategic shifts in healthcare delivery, including a significant share sale by CFO Oluyemi Okupe and a legal investigation by Berger Montague regarding a frozen collaboration with Novo Nordisk. The company faces financial challenges despite strong revenue, with concerns over profitability margins, high valuation metrics, and negative operating cash flow, balanced by a substantial ending cash position. The article highlights the intricate balance of growth, legal challenges, and insider transactions that influence HIMS's market trajectory.",
      "banner_image": "https://content.timothysykes.com/cdn-cgi/image/quality=90,format=webp,width=740/https://content.timothysykes.com/wp-content/uploads/2025/10/hims-hers-facesbr-financial-challenges-ahead.png",
      "source": "timothysykes.com",
      "category_within_source": "General",
      "source_domain": "timothysykes.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.903266"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.732129"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.635902"
        },
        {
          "topic": "finance",
          "relevance_score": "0.514153"
        },
        {
          "topic": "economy_macro",
          "relevance_score": "0.327025"
        }
      ],
      "overall_sentiment_score": 0.042149,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.312499",
          "ticker_sentiment_score": "0.008331",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "How To Buy HIMS For A 24% Discount, Or Achieve An 82% Annual Return - Barchart.com",
      "url": "https://www.barchart.com/story/news/35490104/how-to-buy-hims-for-a-24-discount-or-achieve-an-82-annual-return",
      "time_published": "20251016T110002",
      "authors": [
        "Gavin McMaster"
      ],
      "summary": "This article explains how to use cash-secured put options on Hims & Hers Health (HIMS) to either acquire the stock at a significant discount or generate a high annualized return. It details a specific trade example with HIMS, where selling a November 7 put option with a $50 strike price offers a potential 81.77% annualized return or a 24.24% discount if assigned. The article also provides company details, analyst ratings, and implied volatility information for HIMS, highlighting the risks involved in options trading.",
      "banner_image": "https://media.barchart.com/contributors-admin/common-images/images/Stocks%2C%20Markets%2C%20%26%20Global%20Economy/Options/Words%20options%20trading%20written%20on%20a%20book%20by%20Vitalii%20Vodolazskyi%20via%20Shutterstock.jpg",
      "source": "Barchart.com",
      "category_within_source": "General",
      "source_domain": "Barchart.com",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.923500"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.720251"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.525848"
        }
      ],
      "overall_sentiment_score": 0.011797,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.332316",
          "ticker_sentiment_score": "0.037964",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hims & Hers launches perimenopause and menopause care on platform By Investing.com - Investing.com Canada",
      "url": "https://ca.investing.com/news/company-news/hims--hers-launches-perimenopause-and-menopause-care-on-platform-93CH-4248320",
      "time_published": "20251015T134539",
      "authors": [
        "Investing.com"
      ],
      "summary": "The article reports that Hims & Hers has launched perimenopause and menopause care services on its platform. This expansion signifies the company's move into addressing women's health concerns related to aging.",
      "banner_image": null,
      "source": "Investing.com Canada",
      "category_within_source": "General",
      "source_domain": "Investing.com Canada",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.017069,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.303400",
          "ticker_sentiment_score": "0.032276",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hers Launches Menopause and Perimenopause Specialty, Taking the Next Step Toward $1B of Hers Revenue in 2026 - MarketScreener",
      "url": "https://www.marketscreener.com/news/hers-launches-menopause-and-perimenopause-specialty-taking-the-next-step-toward-1b-of-hers-revenue-ce7d5adfd888f126",
      "time_published": "20251015T131005",
      "authors": [
        "Business Wire"
      ],
      "summary": "Hims & Hers Health, Inc. announced the launch of a new women's health specialty focused on perimenopause and menopause, aiming to provide affordable treatment plans. This expansion builds on the Hers platform's existing user base of over half a million subscribers and is projected to contribute to the company surpassing $1 billion in annual revenue by 2026. The new service addresses a significant gap in women's healthcare by offering personalized treatment plans, including prescription medications, through independent licensed providers.",
      "banner_image": "https://mms.businesswire.com/media/20251015848037/en/2609991/4/2025_Hers_Menopause_BusinessWire_2.jpg",
      "source": "MarketScreener",
      "category_within_source": "General",
      "source_domain": "MarketScreener",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.828540"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.508280"
        },
        {
          "topic": "finance",
          "relevance_score": "0.446639"
        }
      ],
      "overall_sentiment_score": 0.007596,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.326249",
          "ticker_sentiment_score": "0.007045",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hims & Hers stock rises after launching menopause treatment services By Investing.com - Investing.com Canada",
      "url": "https://ca.investing.com/news/stock-market-news/hims--hers-stock-rises-after-launching-menopause-treatment-services-93CH-4248266",
      "time_published": "20251015T130314",
      "authors": [
        "Investing.com"
      ],
      "summary": "The article reports that Hims & Hers stock rose following the launch of its menopause treatment services. However, the full article content is not available due to a client-side exception on the website.",
      "banner_image": null,
      "source": "Investing.com Canada",
      "category_within_source": "General",
      "source_domain": "Investing.com Canada",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.943960"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.640023"
        }
      ],
      "overall_sentiment_score": 0.02445,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.333466",
          "ticker_sentiment_score": "0.013995",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hers Launches Menopause and Perimenopause Specialty, Taking the Next Step Toward $1B of Hers Revenue in 2026 - itemonline.com",
      "url": "https://www.itemonline.com/hers-launches-menopause-and-perimenopause-specialty-taking-the-next-step-toward-1b-of-hers-revenue/article_84fce55a-6db1-5c2d-85e3-05bc17b15fec.html",
      "time_published": "20251015T125916",
      "authors": [
        "Business Wire"
      ],
      "summary": "Hims & Hers Health, Inc. (NYSE: HIMS) has launched a new specialty in women\u2019s health focusing on perimenopause and menopause, aiming to provide affordable and tailored treatment plans. This expansion builds on Hers' existing platform, which has over half a million subscribers, and positions the company to surpass $1 billion in annual revenue by 2026. The initiative addresses a significant gap in healthcare access for women experiencing menopause, offering personalized care through licensed providers and various prescription medications.",
      "banner_image": "https://bloximages.chicago2.vip.townnews.com/itemonline.com/content/tncms/assets/v3/editorial/c/64/c6422826-e546-547d-a386-045a8855ac90/68ef9c49f1978.image.jpg",
      "source": "itemonline.com",
      "category_within_source": "General",
      "source_domain": "itemonline.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.916679"
        },
        {
          "topic": "retail_wholesale",
          "relevance_score": "0.738198"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.535914"
        }
      ],
      "overall_sentiment_score": 0.031047,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.305105",
          "ticker_sentiment_score": "0.042655",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hims & Hers Health, Inc. Experiences Evaluation Revision Amid Strong Market Performance - Markets Mojo",
      "url": "https://www.marketsmojo.com/news/stocks-in-action/hims-hers-health-inc-technical-trend-shifts-from-bullish-to-mildly-bullish-amid-stock-price-increase-3619991",
      "time_published": "20251014T201013",
      "authors": [],
      "summary": "Hims & Hers Health, Inc. has seen its evaluation revised due to current market dynamics, demonstrating significant outperformance against the S&P 500 with impressive returns over the past year and three years. Technical indicators show a mixed outlook, with both bullish and mildly bearish trends depending on the timeframe. The company's resilience and growth potential are highlighted amidst ongoing market challenges.",
      "banner_image": "https://i.marketsmojo.com/newsimg/2025/10/HimsHersHealthI_technicaldot_3619991.png",
      "source": "Markets Mojo",
      "category_within_source": "General",
      "source_domain": "Markets Mojo",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.917375"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.948349"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.835754"
        }
      ],
      "overall_sentiment_score": 0.002382,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.307508",
          "ticker_sentiment_score": "0.047428",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hims & Hers to Announce Third Quarter 2025 Financial Results on November 3, 2025 - MarketScreener",
      "url": "https://www.marketscreener.com/news/hims-hers-to-announce-third-quarter-2025-financial-results-on-november-3-2025-ce7d5ad8d081fe2d",
      "time_published": "20251013T200607",
      "authors": [
        "Business Wire"
      ],
      "summary": "Hims & Hers Health, Inc. announced that it will report its third quarter 2025 financial results after market close on Monday, November 3, 2025. The company will host a live conference call the same day at 5:00 p.m. ET to discuss the results. Hims & Hers is a leading health and wellness platform focused on personalized care.",
      "banner_image": null,
      "source": "MarketScreener",
      "category_within_source": "General",
      "source_domain": "MarketScreener",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.741987"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.608704"
        }
      ],
      "overall_sentiment_score": 0.006116,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.347160",
          "ticker_sentiment_score": "0.007241",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Callan Family Office LLC Grows Stake in Hims & Hers Health, Inc. $HIMS - MarketBeat",
      "url": "https://www.marketbeat.com/instant-alerts/filing-callan-family-office-llc-grows-stake-in-hims-hers-health-inc-hims-2025-10-12/",
      "time_published": "20251012T081110",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Callan Family Office LLC significantly increased its stake in Hims & Hers Health, Inc. by 70.7% in Q2, now owning 34,004 shares valued at $1.7 million. This comes amid fluctuating stock performance and recent insider share sales, despite the company reporting strong revenue growth of 72.6% year-over-year. Analysts currently hold a consensus rating of \"Reduce\" for the stock, with an average target price of $38.92.",
      "banner_image": "https://www.marketbeat.com/logos/hims--hers-health-inc-logo-1200x675.jpg?v=20240503131444",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.941380"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.710189"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.616959"
        },
        {
          "topic": "finance",
          "relevance_score": "0.414414"
        }
      ],
      "overall_sentiment_score": 0.048323,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.322632",
          "ticker_sentiment_score": "0.024663",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Kingswood Wealth Advisors LLC Makes New $241,000 Investment in Hims & Hers Health, Inc. $HIMS - MarketBeat",
      "url": "https://www.marketbeat.com/instant-alerts/filing-kingswood-wealth-advisors-llc-makes-new-241000-investment-in-hims-hers-health-inc-hims-2025-10-12/",
      "time_published": "20251012T074502",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Kingswood Wealth Advisors LLC recently made a new investment of $241,000 in Hims & Hers Health, acquiring 4,837 shares. This comes amidst mixed signals for Hims & Hers Health, with some research firms downgrading the stock while other institutional investors have increased their holdings. Insider transactions also show CEO Andrew Dudum sold a significant number of shares.",
      "banner_image": "https://www.marketbeat.com/logos/hims--hers-health-inc-logo-1200x675.jpg?v=20240503131444",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.942038"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.801261"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.729715"
        }
      ],
      "overall_sentiment_score": 0.025306,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.333290",
          "ticker_sentiment_score": "0.028604",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of \"Reduce\" from Brokerages",
      "url": "https://www.marketbeat.com/instant-alerts/hims-hers-health-inc-nysehims-receives-average-recommendation-of-reduce-from-brokerages-2025-10-12/",
      "time_published": "20251012T062834",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Hims & Hers Health, Inc. (NYSE:HIMS) has received an average \"Reduce\" recommendation from analysts, with a target price of $38.9167. The company reported a 72.6% year-over-year revenue increase but missed EPS estimates for the recent quarter. Insider selling, including CEO Andrew Dudum's sale of 660,000 shares, has also been noted, with insiders selling over $83 million worth of stock in the last three months.",
      "banner_image": "https://www.marketbeat.com/logos/hims--hers-health-inc-logo-1200x675.jpg?v=20240503131444",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.910816"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.730338"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.633170"
        },
        {
          "topic": "finance",
          "relevance_score": "0.510113"
        }
      ],
      "overall_sentiment_score": 0.006825,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.326441",
          "ticker_sentiment_score": "0.033791",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Recover Investment Losses: Levi & Korsinsky Files Class Action Against Hims & Hers Health, Inc. (HIMS)",
      "url": "https://www.qcnews.com/business/press-releases/accesswire/1064356/recover-investment-losses-levi-korsinsky-files-class-action-against-hims-hers-health-inc-hims",
      "time_published": "20250822T115700",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against Hims & Hers Health, Inc. (NYSE:HIMS) on behalf of shareholders who suffered losses between April 29, 2025, and June 23, 2025. The lawsuit alleges that Hims made false statements by deceptively promoting and selling illegitimate versions of Wegovy\u00ae, which put patient safety at risk and could lead to the termination of their collaboration with Novo Nordisk. Investors are encouraged to seek information about their rights to recovery without cost or obligation.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1064356",
      "source": "Queen City News",
      "category_within_source": "General",
      "source_domain": "Queen City News",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.906525"
        },
        {
          "topic": "finance",
          "relevance_score": "0.839371"
        }
      ],
      "overall_sentiment_score": -0.411487,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.417139",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Securities Class Action Lawsuit Filed Against Hims & Hers Health, Inc. (HIMS) - Levi & Korsinsky Represents Shareholders",
      "url": "https://www.cbs42.com/business/press-releases/accesswire/1064218/securities-class-action-lawsuit-filed-against-hims-hers-health-inc-hims-levi-korsinsky-represents-shareholders",
      "time_published": "20250822T103700",
      "authors": [
        "NULL"
      ],
      "summary": "A class action securities lawsuit has been filed against Hims & Hers Health, Inc. (HIMS) by Levi & Korsinsky, LLP, representing shareholders who suffered losses between April 29, 2025, and June 23, 2025. The lawsuit alleges that Hims engaged in deceptive promotion of \"knockoff\" Wegovy versions, putting patient safety at risk and jeopardizing its collaboration with Novo Nordisk. Shareholders are encouraged to learn about their rights to seek recovery.",
      "banner_image": "NULL",
      "source": "CBS 42",
      "category_within_source": "General",
      "source_domain": "CBS 42",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.932480"
        },
        {
          "topic": "finance",
          "relevance_score": "0.716347"
        }
      ],
      "overall_sentiment_score": -0.924334,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.928490",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit And Upcoming Deadlines - HIMS",
      "url": "https://www.abc4.com/business/press-releases/accesswire/1060582/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-hims-hers-health-inc-of-class-action-lawsuit-and-upcoming-deadlines-hims",
      "time_published": "20250818T100000",
      "authors": [
        "NULL"
      ],
      "summary": "Pomerantz LLP has filed a class action lawsuit against Hims & Hers Health, Inc. (NYSE:HIMS) on behalf of investors who incurred losses. The lawsuit alleges securities fraud following Novo Nordisk's termination of a collaboration with Hims & Hers, citing the sale of \"illegitimate, knockoff versions of Wegovy\u00ae\" and \"deceptive promotion.\" This news led to a significant drop in Hims & Hers' stock price.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1060582",
      "source": "ABC4 Utah",
      "category_within_source": "General",
      "source_domain": "ABC4 Utah",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.914448"
        },
        {
          "topic": "finance",
          "relevance_score": "0.826323"
        }
      ],
      "overall_sentiment_score": 0.00121,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.328371",
          "ticker_sentiment_score": "0.017788",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "HIMS INVESTOR NOTICE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit",
      "url": "https://www.prnewswire.com/news-releases/hims-investor-notice-hims--hers-health-inc-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-302531277.html",
      "time_published": "20250817T092500",
      "authors": [],
      "summary": "Robbins Geller Rudman & Dowd LLP announces a shareholder class action lawsuit against Hims & Hers Health, Inc. for alleged securities law violations. Investors who purchased HIMS securities between April 29, 2025, and June 23, 2025, have an opportunity to seek appointment as lead plaintiff. The lawsuit alleges that Hims & Hers engaged in deceptive promotion of \"knockoff versions of Wegovy\u00ae\" which led to the termination of a collaboration with Novo Nordisk A/S and a significant drop in stock price.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.945583"
        },
        {
          "topic": "finance",
          "relevance_score": "0.815048"
        }
      ],
      "overall_sentiment_score": -0.629494,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.609686",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "HIMS LAWSUIT ALERT: The Gross Law Firm Notifies Hims & Hers Health, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline",
      "url": "https://www.morningstar.com/news/pr-newswire/20250814ny51041/hims-lawsuit-alert-the-gross-law-firm-notifies-hims-hers-health-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline",
      "time_published": "20250814T124500",
      "authors": [],
      "summary": "The Gross Law Firm has issued a class action lawsuit alert for investors of Hims & Hers Health, Inc. (NYSE: HIMS). The lawsuit alleges that Hims engaged in deceptive promotion and selling of illegitimate, knockoff versions of Wegovy\u00ae, risking patient safety and potential termination of their collaboration with Novo Nordisk. Shareholders who purchased HIMS shares between April 29, 2025, and June 23, 2025, are encouraged to contact the firm by the August 25, 2025, deadline to seek lead plaintiff appointment.",
      "banner_image": null,
      "source": "Morningstar",
      "category_within_source": "General",
      "source_domain": "Morningstar",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": -0.721447,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.731268",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Hims & Hers Health, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - HIMS",
      "url": "https://www.newmediawire.com/news/hims-hers-health-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-hims-7081782",
      "time_published": "20250807T060909",
      "authors": [],
      "summary": "Levi & Korsinsky, LLP has filed a class action securities lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who suffered losses due to alleged securities fraud between April 29, 2025, and June 23, 2025. The lawsuit claims Hims engaged in deceptive promotion of \"knockoff\" Wegovy\u00ae and concealed the risk of collaboration termination with Novo Nordisk. Affected investors have until August 25, 2025, to seek a lead plaintiff appointment.",
      "banner_image": "https://iprsoftwaremedia.com/270/files/202506/8e32c07b62627194_1750452756980_61bb501d8104f75c060f41d9_logo",
      "source": "NewMediaWire",
      "category_within_source": "General",
      "source_domain": "NewMediaWire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.902049"
        },
        {
          "topic": "finance",
          "relevance_score": "0.801580"
        }
      ],
      "overall_sentiment_score": -0.433258,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.409918",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Investor Alert: Deadline Approaching to Join Hims & Hers Health, Inc. (HIMS) Class Action - Contact Levi & Korsinsky",
      "url": "https://fox40.com/business/press-releases/accesswire/1052950/investor-alert-deadline-approaching-to-join-hims-hers-health-inc-hims-class-action-contact-levi-korsinsky",
      "time_published": "20250725T080954",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky, LLP has issued an investor alert regarding a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS). The lawsuit alleges that the company made false statements and concealed information about promoting \"knockoff\" versions of Wegovy\u00ae, which put patient safety at risk and could lead to the termination of their collaboration with Novo Nordisk. Investors who suffered losses between April 29, 2025, and June 23, 2025, are encouraged to contact the firm to learn about their rights to recovery under federal securities laws.",
      "banner_image": "https://i0.wp.com/fox40.com/wp-content/uploads/sites/13/2025/11/GettyImages-943697000-1-1-3-2-2-e1697928619486-1-e1698682964713-1_92da3b-e1743430271414_4dfb5e.jpg?w=2000&ssl=1",
      "source": "FOX40 News",
      "category_within_source": "General",
      "source_domain": "FOX40 News",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.947444"
        },
        {
          "topic": "finance",
          "relevance_score": "0.718544"
        }
      ],
      "overall_sentiment_score": -0.648554,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.616203",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "HIMS STOCK NOTICE: Hims & Hers Health, Inc. Investors are Notified the Company is being Sued for Fraud and to Contact BFA Law by August 25",
      "url": "https://www.newsfilecorp.com/release/259851/HIMS-STOCK-NOTICE-Hims-Hers-Health-Inc.-Investors-are-Notified-the-Company-is-being-Sued-for-Fraud-and-to-Contact-BFA-Law-by-August-25",
      "time_published": "20250725T070800",
      "authors": [],
      "summary": "Hims & Hers Health, Inc. (NYSE: HIMS) is facing a securities fraud lawsuit alleging the company misrepresented its partnership with Novo Nordisk and its compliance with FDA regulations regarding compounded semaglutide. Investors have until August 25, 2025, to seek appointment as lead plaintiff in the case, which led to a 34% stock decline on June 23, 2025, after Novo Nordisk terminated the partnership over \"deceptive promotion.\" Bleichmar Fonti & Auld LLP is representing investors, offering contingency fee representation.",
      "banner_image": "https://images.newsfilecorp.com/files/10531/259851_3c6c3cfa04d00bf7_logo.jpg",
      "source": "Newsfile",
      "category_within_source": "General",
      "source_domain": "Newsfile",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.942756"
        },
        {
          "topic": "finance",
          "relevance_score": "0.710036"
        }
      ],
      "overall_sentiment_score": -0.905062,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.914721",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "HIMS STOCK: Hims & Hers Health, Inc. Investors Are Notified of The August 25 Class Action Deadline - Contact BFA Law if You Suffered Losses",
      "url": "https://fox40.com/business/press-releases/accesswire/1052678/hims-stock-hims-hers-health-inc-investors-are-notified-of-the-august-25-class-action-deadline-contact-bfa-law-if-you-suffered-losses",
      "time_published": "20250725T040900",
      "authors": [
        "NULL"
      ],
      "summary": "Bleichmar Fonti & Auld LLP has announced a class action lawsuit against Hims & Hers Health, Inc. (NYSE:HIMS) and its executives for alleged securities law violations. The lawsuit claims Hims & Hers misrepresented its collaboration with Novo Nordisk regarding the sale of Wegovy and compounded semaglutide, leading to a significant stock drop when Novo Nordisk terminated the partnership due to \"deceptive promotion.\" Investors who suffered losses have until August 25, 2025, to seek appointment as lead plaintiff.",
      "banner_image": "https://app.accessnewswire.com/imagelibrary/752dee78-f708-4c09-9062-7f66794876b2/1052678/image.jpeg",
      "source": "FOX40 News",
      "category_within_source": "General",
      "source_domain": "FOX40 News",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.929265"
        },
        {
          "topic": "finance",
          "relevance_score": "0.734080"
        }
      ],
      "overall_sentiment_score": -0.449805,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.423875",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Growth or Bubble? Hims & Hers\u2019 Stock Surge Unveiled",
      "url": "https://stockstotrade.com/news/hims-hers-health-inc-hims-news-2025_07_23/",
      "time_published": "20250723T140400",
      "authors": [
        "Tim Bohen",
        "Ben Sturgill",
        "Ellis Hobbs"
      ],
      "summary": "Hims & Hers Health Inc.'s stock surged by 15.56% following strategic partnerships and international expansion plans into Canada by 2026. Despite strong financial figures, including $1.47B revenue and a 77% gross margin, the company faces a class-action lawsuit and a high price-to-earnings ratio, prompting caution among investors. The upcoming Q2 earnings announcement on August 4, 2025, is highly anticipated to further clarify its growth trajectory amidst these challenges.",
      "banner_image": null,
      "source": "StocksToTrade",
      "category_within_source": "General",
      "source_domain": "StocksToTrade",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.906257"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.849000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.909917"
        }
      ],
      "overall_sentiment_score": 0.325886,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.337364",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "HIMS & HERS HEALTH, INC. (NYSE: HIMS) SHAREHOLDER ALERT",
      "url": "https://www.globenewswire.com/news-release/2025/07/21/3118696/0/en/HIMS-HERS-HEALTH-INC-NYSE-HIMS-SHAREHOLDER-ALERT-Bernstein-Liebhard-LLP-Reminds-Hims-Hers-Health-Inc-Investors-of-Upcoming-Deadline.html",
      "time_published": "20250721T081500",
      "authors": [
        "Bernstein Liebhard LLP"
      ],
      "summary": "Bernstein Liebhard LLP reminds investors of an upcoming deadline for a securities fraud class action lawsuit against Hims & Hers Health, Inc. Investors who purchased shares between April 29, 2025, and June 22, 2025, inclusive, and experienced losses, are encouraged to inquire about their legal options. The lawsuit alleges that Hims made misrepresentations regarding the promotion and selling of Wegovy.",
      "banner_image": null,
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.943307"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.713786"
        }
      ],
      "overall_sentiment_score": -0.408549,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.441002",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "HIMS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!",
      "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/hims-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-1043494",
      "time_published": "20250701T070000",
      "authors": [
        "NULL"
      ],
      "summary": "Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Hims & Hers Health, Inc. (NYSE:HIMS) and its officers. The lawsuit alleges that Hims & Hers made materially false and/or misleading statements and failed to disclose critical information regarding their business operations, particularly concerning their alleged \"deceptive promotion and selling of illegitimate, knockoff versions of Wegovy\u00ae.\" Investors who purchased Hims & Hers securities between April 29, 2025, and June 23, 2025, are encouraged to join the case, with a deadline of August 25, 2025, to request to be appointed as lead plaintiff.",
      "banner_image": "https://irp.cdn-website.com/b585153d/dms3rep/multi/PURE_WHITE.svg",
      "source": "ACCESS Newswire",
      "category_within_source": "General",
      "source_domain": "ACCESS Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.913146"
        },
        {
          "topic": "finance",
          "relevance_score": "0.732308"
        }
      ],
      "overall_sentiment_score": 0.045943,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.309286",
          "ticker_sentiment_score": "0.040375",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over \"Deceptive\" Marketing of Wegovy\u00ae- Hagens Berman",
      "url": "https://www.prnewswire.com/news-releases/hims--hers-health-inc-hims-faces-securities-class-actions-after-novo-nordisk-cancels-partnership-over-deceptive-marketing-of-wegovy-hagens-berman-302492903.html",
      "time_published": "20250627T090100",
      "authors": [
        "Hagens Berman Sobol Shapiro LLP"
      ],
      "summary": "Hagens Berman announced two securities class action lawsuits against Hims & Hers Health, Inc. (HIMS) and its executives, representing investors who bought HIMS securities between April 29, 2025, and June 23, 2025. This action follows Novo Nordisk's termination of its collaboration with Hims & Hers due to concerns over \"deceptive\" marketing and sales of Wegovy\u00ae, which caused a 30% drop in HIMS share price. The lawsuits allege that Hims & Hers made false statements and engaged in deceptive promotion of knockoff Wegovy\u00ae versions, jeopardizing patient safety and the partnership.",
      "banner_image": "NULL",
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.924024"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.731367"
        }
      ],
      "overall_sentiment_score": -0.52282,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.529505",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Hims & Hers Health, Inc. (HIMS) Shares Crash After Novo Nordisk Cancels Partnership Over \"Deceptive\" Marketing of Wegovy, Faces Investor Scrutiny- Hagens Berman",
      "url": "https://www.prnewswire.com/news-releases/hims--hers-health-inc-hims-shares-crash-after-novo-nordisk-cancels-partnership-over-deceptive-marketing-of-wegovy-faces-investor-scrutiny-hagens-berman-302491131.html",
      "time_published": "20250625T140800",
      "authors": [],
      "summary": "Hims & Hers Health, Inc. (HIMS) shares crashed over 30% after Novo Nordisk terminated their partnership, citing concerns about Hims & Hers' \"deceptive\" marketing and \"illegal mass compounding\" of Wegovy\u00ae. Hagens Berman has initiated an investigation into possible securities law violations and is urging affected investors and individuals with relevant information to come forward.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.814646"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.927940"
        }
      ],
      "overall_sentiment_score": -0.845362,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.802982",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Hims & Hers Health Inc. issues $1B in convertible notes",
      "url": "https://www.investing.com/news/sec-filings/hims--hers-health-inc-issues-1b-in-convertible-notes-93CH-4043464",
      "time_published": "20250513T174200",
      "authors": [
        "Investing.com"
      ],
      "summary": "Hims & Hers Health Inc. has issued $1 billion in 0.00% convertible senior notes due 2030 through a private offering to qualified institutional buyers. This financing move, which includes capped call transactions to minimize dilution, aims to raise capital for the company's growth strategies. The company's stock has seen significant performance, and the article also highlights recent positive analyst revisions and strategic appointments.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.941394"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.831965"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.704480"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.643068"
        }
      ],
      "overall_sentiment_score": 0.325948,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.312829",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Hims & Hers Health, Inc. Reports Third Quarter 2024 Financial Results",
      "url": "https://www.businesswire.com/news/home/20241104902300/en/Hims-Hers-Health-Inc.-Reports-Third-Quarter-2024-Financial-Results",
      "time_published": "20241231T235959",
      "authors": [],
      "summary": "Hims & Hers Health, Inc. announced strong financial results for the third quarter of 2024, with revenue up 77% year-over-year to $401.6 million and net income of $75.6 million. The company's subscriber base grew to 2.0 million, a 44% increase from the previous year. Hims & Hers also raised its full-year 2024 revenue guidance to a range of $1.460 billion to $1.465 billion and Adjusted EBITDA guidance to $173 million to $178 million, demonstrating continued growth and profitability.",
      "banner_image": null,
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.915431"
        },
        {
          "topic": "retail_wholesale",
          "relevance_score": "0.736701"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.615526"
        },
        {
          "topic": "technology",
          "relevance_score": "0.604314"
        }
      ],
      "overall_sentiment_score": 0.721894,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.732478",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "How Our Technology Powers a World-Class Customer Experience",
      "url": "https://news.hims.com/newsroom/how-our-technology-powers-a-world-class-customer-experience",
      "time_published": "20241104T000000",
      "authors": [
        "Hims & Hers"
      ],
      "summary": "Hims & Hers leverages its proprietary technology stack, including its EMR, MedMatch by Hims & Hers, and a clever routing system, to deliver high-quality, personalized healthcare. This technology aims to reduce administrative burdens for providers, enhance patient safety, and improve efficiency. The platform utilizes AI and machine learning to offer personalized treatment recommendations and streamline customer support, resulting in improved patient adherence and reduced wait times.",
      "banner_image": null,
      "source": "Hims & Hers Newsroom",
      "category_within_source": "General",
      "source_domain": "Hims & Hers Newsroom",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.935663"
        },
        {
          "topic": "technology",
          "relevance_score": "0.818401"
        }
      ],
      "overall_sentiment_score": 0.46922,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.465715",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "4 Things to Know From Our Q2 Earnings Report",
      "url": "https://news.hims.com/newsroom/4-things-to-know-from-our-q2-earnings-report",
      "time_published": "20240805T000000",
      "authors": [
        "Andrew Dudum"
      ],
      "summary": "Hims & Hers achieved significant growth in Q2 2024, adding over 155,000 net new subscribers and reaching nearly 1.9 million active total subscribers, driven by its focus on personalized care across five specialties. The company is experiencing a transformative moment, particularly with its Weight Loss specialty and the successful integration of personalized GLP-1 solutions. Hims & Hers is also strengthening its leadership with new board additions, underscoring its commitment to innovation and expanding healthcare accessibility.",
      "banner_image": null,
      "source": "Hims & Hers Newsroom",
      "category_within_source": "General",
      "source_domain": "Hims & Hers Newsroom",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.925691"
        }
      ],
      "overall_sentiment_score": 0.508775,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.513678",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Hims & Hers Announces Access to GLP-1 Injections, Passing Cost Savings Onto Customers",
      "url": "https://investors.hims.com/news/news-details/2024/Hims--Hers-Announces-Access-to-GLP-1-Injections-Passing-Cost-Savings-Onto-Customers/default.aspx",
      "time_published": "20240520T000000",
      "authors": [],
      "summary": "Hims & Hers announced the addition of GLP-1 injections to its weight loss portfolio, offering an affordable way to access treatment starting as low as $199 a month. This move aims to bypass shortages and high costs associated with branded GLP-1 medications by providing access to compounded versions. The company emphasizes a holistic approach to weight management and expects its weight loss offering to exceed $100M in revenue by the end of 2025.",
      "banner_image": null,
      "source": "Hims Investor Relations",
      "category_within_source": "General",
      "source_domain": "Hims Investor Relations",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.930100"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.614430"
        }
      ],
      "overall_sentiment_score": 0.454151,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.492621",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Hers and GNC to Collaborate on Health and Wellness Solutions",
      "url": "https://investors.hims.com/news/news-details/2022/Hims--Hers-and-GNC-to-Collaborate-on-Health-and-Wellness-Solutions/default.aspx",
      "time_published": "20220215T165647",
      "authors": [],
      "summary": "Hims & Hers Health, Inc. announced a partnership with GNC to offer health and wellness solutions at select GNC stores nationwide and online at GNC.com. This collaboration aims to broaden accessibility for Hims & Hers hair care offerings, including minoxidil topical foams and solutions, shampoos, and conditioners. The partnership is part of Hims & Hers' strategy to build a trusted, nationwide brand and expand its mass market accessibility through retail integrations.",
      "banner_image": null,
      "source": "Hims Investor Relations",
      "category_within_source": "General",
      "source_domain": "Hims Investor Relations",
      "topics": [
        {
          "topic": "retail_wholesale",
          "relevance_score": "0.920777"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.818032"
        }
      ],
      "overall_sentiment_score": 0.315128,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.407732",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "WBA",
          "relevance_score": "0.626400",
          "ticker_sentiment_score": "0.206259",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Amid Rapid Growth, Vida Health Hires Patrick Carroll, MD as Chief Medical Officer",
      "url": "https://www.businesswire.com/news/home/20220124005084/en/Amid-Rapid-Growth-Vida-Health-Hires-Patrick-Carroll-MD-as-Chief-Medical-Officer",
      "time_published": "20220124T165647",
      "authors": [],
      "summary": "Vida Health has announced the hiring of Patrick Carroll, MD, as its new Chief Medical Officer, bringing extensive experience from Hims & Hers and Walgreens. Dr. Carroll will lead Vida's clinical strategy, research, and medical cost-saving initiatives, overseeing a large team of providers. This strategic hire aims to strengthen Vida Health's position in virtual chronic care as the company continues its rapid growth.",
      "banner_image": "https://mms.businesswire.com/media/20220124005084/en/925345/4/Patrick_Carroll_.jpg",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.014558,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.347519",
          "ticker_sentiment_score": "0.045046",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    }
  ]
}